Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Recruitment status was: Recruiting
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients at risk of developing myelodysplastic syndrome may help doctors learn more about changes that occur in DNA and identify biomarkers related to disorders of the blood and bone marrow.
PURPOSE: This research study is looking at biomarkers in patients at risk of developing myelodysplastic syndrome or other disorders and in healthy participants.
Genetic: DNA methylation analysis
Genetic: RNA analysis
Genetic: cytogenetic analysis
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Other: laboratory biomarker analysis
|Official Title:||Molecular and Functional Characterisation of Bone Marrow Function in Normal Subjects, Myelodysplastic Syndromes (MDS) and Secondary Disorders of Heamatopoiesis|
- Identification of novel biomarkers of disease [ Designated as safety issue: No ]
- Identification of novel biomarkers of disease progression from myelodysplastic syndromes to acute myeloid leukemia [ Designated as safety issue: No ]
- Comprehension of genesis of anemia in cancer [ Designated as safety issue: No ]
|Study Start Date:||January 2007|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
- To identify novel biomarkers of disease that would help in the initial diagnosis of myelodysplastic syndromes (MDS).
- To understand the genesis of anemia in cancers.
- To identify novel biomarkers of disease that predict progression of MDS to acute myeloid leukemia.
OUTLINE: Blood and bone marrow samples are collected. Hemopoietic stem cells (HSC) and progenitor cells are isolated from samples for analysis. Some of these HSC and progenitor cells are used for functional assays. From the rest of the cells, DNA, RNA, and protein is extracted for molecular analyses, including gene mutation analysis, gene methylation assays, chromatin immunoprecipitation, microarray, and real-time polymerase chain reaction.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899327
|Oxford Radcliffe Hospital|
|Oxford, England, United Kingdom, 0X3 9DU|
|Principal Investigator:||Vyas Paresh, MD||Oxford University Hospitals NHS Trust|